EGFR and non-small cell lung carcinoma: In this respect, our study suggests that EGFR mutant NSCLC patients who progress after gefitinib and subsequent chemotherapy and do not have serum p.T790M do benefit more from the rechallenge with gefitinib as compared with p.T790M-positive patients.